These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34521352)

  • 1. The choice of negative control antisense oligonucleotides dramatically impacts downstream analysis depending on the cellular background.
    Ducoli L; Agrawal S; Hon CC; Ramilowski JA; Sibler E; Tagami M; Itoh M; Kondo N; Abugessaisa I; Hasegawa A; Kasukawa T; Suzuki H; Carninci P; Shin JW; de Hoon MJL; Detmar M
    BMC Genom Data; 2021 Sep; 22(1):33. PubMed ID: 34521352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tips for Successful lncRNA Knockdown Using Gapmers.
    Lennox KA; Behlke MA
    Methods Mol Biol; 2020; 2176():121-140. PubMed ID: 32865787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LETR1 is a lymphatic endothelial-specific lncRNA governing cell proliferation and migration through KLF4 and SEMA3C.
    Ducoli L; Agrawal S; Sibler E; Kouno T; Tacconi C; Hon CC; Berger SD; Müllhaupt D; He Y; Kim J; D'Addio M; Dieterich LC; Carninci P; de Hoon MJL; Shin JW; Detmar M
    Nat Commun; 2021 Feb; 12(1):925. PubMed ID: 33568674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish.
    Pauli A; Montague TG; Lennox KA; Behlke MA; Schier AF
    PLoS One; 2015; 10(10):e0139504. PubMed ID: 26436892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.
    Lennox KA; Behlke MA
    Nucleic Acids Res; 2016 Jan; 44(2):863-77. PubMed ID: 26578588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of nuclear-retained long noncoding RNAs using modified DNA antisense oligonucleotides.
    Zong X; Huang L; Tripathi V; Peralta R; Freier SM; Guo S; Prasanth KV
    Methods Mol Biol; 2015; 1262():321-31. PubMed ID: 25555591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
    Maruyama R; Yokota T
    Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
    Iwashita S; Shoji T; Koizumi M
    Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Oligonucleotides as a Tool for Prolonged Knockdown of Nuclear lncRNAs in Human Cell Lines.
    Montiel-Manriquez R; Castro-Hernández C; Arriaga-Canon C; Herrera LA
    J Vis Exp; 2023 Sep; (199):. PubMed ID: 37677025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
    Zhou T; Kim Y; MacLeod AR
    Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense long non‑coding RNA WEE2‑AS1 regulates human vascular endothelial cell viability via cell cycle G2/M transition in arteriosclerosis obliterans.
    Jiang B; Wang R; Lin Z; Ma J; Cui J; Wang M; Liu R; Wu W; Zhang C; Li W; Wang S
    Mol Med Rep; 2020 Dec; 22(6):5069-5082. PubMed ID: 33174040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
    Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
    Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Administration of Therapeutic Antisense Oligonucleotides.
    Statello L; Ali MM; Kanduri C
    Methods Mol Biol; 2021; 2254():273-282. PubMed ID: 33326082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
    Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
    Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Oligonucleotide Embedded Context Responsive Nanoparticles Derived from Synthetic Ionizable Lipids for lncRNA Targeted Therapy of Breast Cancer.
    Sarkar S; Moitra P; Bera S; Bhattacharya S
    ACS Appl Mater Interfaces; 2024 Sep; 16(35):45871-45887. PubMed ID: 39163516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense-Mediated Transcript Knockdown Triggers Premature Transcription Termination.
    Lee JS; Mendell JT
    Mol Cell; 2020 Mar; 77(5):1044-1054.e3. PubMed ID: 31924448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis.
    Gong N; Teng X; Li J; Liang XJ
    ACS Appl Mater Interfaces; 2019 Jan; 11(1):37-42. PubMed ID: 30548064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi's Sarcoma-Associated Herpesvirus.
    Schifano JM; Corcoran K; Kelkar H; Dittmer DP
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.